When Transfer Of Drug Patent Rights Is Reportable To FTC

Law360, New York (November 12, 2013, 12:42 PM EST) -- ​On Nov. 6, the Federal Trade Commission released finalized amendments to the premerger notification rules (the rule), which clarify when the transfer of pharmaceutical (including biological) patent rights is reportable to the FTC as an asset sale under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended.[1]

The finalized rule did not alter the proposed rule, which was initially released by the FTC for public comment in August 2012. As a result of the rule change, any transfer of exclusive pharmaceutical patent rights is potentially reportable...
To view the full article, register now.